Risk Profiles for Sensorineural Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin-based Chemoradiation

Shorter, Phoebe; Harden, Fiona; Owen, Robert; Panizza, Benedict; Burmeister, Bryan; Sommerville, Jennifer; Mengersen, Kerrie; Foote, Matthew

doi:10.1016/j.jmir.2016.11.005

Cited by 8 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 994 non-duplicate citations were identified by using the selected keywords. After the final review, 66 articles were eligible for inclusion in this study [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] . The study selection process is shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis

Dillard

Lopez-Perez

Martinez

et al. 2022

Cancer Epidemiology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis

Dillard

Lopez-Perez

Martinez

et al. 2022

Cancer Epidemiology

View full text Add to dashboard Cite

“…10 The hearing loss associated with cisplatin and radiotherapy is well documented, following a dose-response relationship in previously published models. [11][12][13][14][15] However, none of these models, not even the most robust model developed by Theunissen et al, 14 can predict hearing loss before treatment because they all require information that is available only after the patient has completed treatment, such as cumulative cisplatin and radiotherapy dose. Thus, these models cannot be incorporated into a pretreatment, shared patient decision-making model in which the risks and benefits of various treatment options are discussed.…”

mentioning

confidence: 99%

Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer

Schuette

Lander

Kallogjeri

et al. 2020

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

IMPORTANCE Accurate, accessible predictions of posttreatment hearing loss for patients with head and neck cancer prior to the initiation of treatment are a necessary part of informed patient decision-making.OBJECTIVE To develop a prediction model for postradiotherapy and/or post-cisplatin chemotherapy hearing loss for patients with head and neck cancer. DESIGN, SETTING, AND PARTICIPANTSA retrospective cohort study was conducted at a tertiary academic medical center among 242 patients (482 ears) with head and neck cancer who were treated with radiotherapy and/or cisplatin from October 1, 2014, to July 31, 2018, and had follow-up audiometric data available. EXPOSURES Radiotherapy and cisplatin chemotherapy.MAIN OUTCOMES AND MEASURES Patient hearing level, as measured by the mean of pure tone audiometry at 1, 2, and 4 kHz on completion of treatment. A multivariable mixed model for predicting the posttreatment pure tone average was developed using only information available to clinicians at the beginning of treatment.RESULTS A total of 242 patients (482 ears; 56 women and 186 men; mean [SD] age, 60 [10] years) were included in the analysis. All patients in the study received radiotherapy, and 105 (43.4%) received cisplatin chemotherapy. The mean (SD) total cumulative cisplatin dose was 298 (109) mg/m 2 . Patients' ears received a mean (SD) cochlear radiotherapy dose of 15 (13) Gy. The fixed-effects predictions from the predictive model agreed with 77% (95% CI, 73%-81%) of the variability in the posttreatment pure tone average. This predictive model also had a sensitivity of 80% and a specificity of 75% for predicting an observed posttreatment pure tone average greater than 35 dB (area under the receiver operating characteristic curve, 0.85). CONCLUSIONS AND RELEVANCETo our knowledge, this study develops the first accurate prediction model of posttreatment hearing in patients with head and neck cancer that is feasible for use in the clinical setting before the initiation of treatment. This research confirms that exposure of the cochlea to cisplatin chemotherapy and radiotherapy is associated with hearing loss in patients with head and neck cancer. Finally, this research motivates future studies of ototoxic effects to better understand the adverse effects of head and neck cancer treatment.

show abstract

“…Toxicities were extracted from the chart as noted by treating physicians clinically. Studies which incorporate formal audiometry testing have been reported showing the effects of cisplatin and radiation dose on ototoxicity and our results are likely underestimates of actual ototoxicity rates, which may affect nearly all patients treated with cisplatin‐based chemotherapy and head and neck radiation . Some authors suggest routine audiometry screening prior to high‐dose cisplatin due to frequent discovery of significant preexisting hearing compromise .…”

Section: Discussionmentioning

confidence: 80%

Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma

et al. 2019

View full text Add to dashboard Cite

Background Triweekly high‐dose cisplatin (100 mg/m2) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC). We compared triweekly 100 mg/m2 with alternative weekly 40 mg/m2 and weekly <40 mg/m2 cisplatin regimens. Methods From 2011 to 2016, 163 patients received concurrent cisplatin and intensity‐modulated radiotherapy for locally advanced HNSCC. Primary endpoints were overall survival (OS) and progression‐free survival. Results Cisplatin weekly <40 mg/m2 showed inferior OS outcomes when compared to weekly 40 mg/m2 (P = 0.084) and triweekly 100 mg/m2 (P = 0.04) regimens. Conclusion Our study displayed inferior outcomes with weekly cisplatin doses under 40 mg/m2, suggesting the inferiority of low‐dose weekly chemotherapy and the need for ongoing randomized trials to further explore 40 vs 100 mg/m2 chemotherapy regimens.

show abstract

Risk Profiles for Sensorineural Hearing Loss in Patients with Head and Neck Cancer Receiving Cisplatin-based Chemoradiation

Cited by 8 publications

References 29 publications

Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis

Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis

Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer

Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma

Contact Info

Product

Resources

About